Literature DB >> 26716031

Incidence and risk factors of chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism.

Suqiao Yang1, Yuanhua Yang1, Zhenguo Zhai1, Tuguang Kuang1, Juanni Gong1, Shuai Zhang1, Jianguo Zhu1, Lirong Liang1, Ying H Shen1, Chen Wang1.   

Abstract

BACKGROUND: Early identification and treatment of chronic thromboembolic pulmonary hypertension (CTEPH) are critical to prevent disease progression. We determined the incidence and risk factors for CTEPH in patients with a first episode of acute pulmonary embolism (PE).
METHODS: In this study, consecutive patients with first-episode acute PE were followed for ≤5 years. Pulmonary hypertension (PH) was screened for by echocardiography. Suspected cases were evaluated by right heart catheterization (RHC) and pulmonary angiography (PA). If invasive procedures were not permitted, PH was diagnosed by systolic pulmonary artery pressure (SPAP) >50 mmHg. Diagnosis of CTEPH was confirmed by PA, ventilation/perfusion (V/Q) lung scan, or computed tomography (CT) PA (CTPA).
RESULTS: Overall, 614 patients with acute PE were included (median follow-up, 3.3 years). Ten patients were diagnosed with CTEPH: cumulative incidence 0.8% [95% confidence interval (CI), 0.0-1.6%] at 1 year, 1.3% (95% CI, 0.3-2.3%) at 2 years, and 1.7% (95% CI, 0.7-2.7%) at 3 years. No cases of CTEPH developed after 3 years. History of lower-limb varicose veins [hazard ratio (HR), 4.3; 95% CI, 1.2-15.4; P=0.024], SPAP >50 mmHg at initial PE episode (HR, 23.5; 95% CI, 2.7-207.6; P=0.005), intermediate-risk PE (HR, 1.2; 95% CI, 1.0-1.4; P=0.030), and CT obstruction index over 30% at 3 months after acute PE (HR, 42.5; 95% CI, 4.4-409.8; P=0.001) were associated with increased risk of CTEPH.
CONCLUSIONS: CTEPH was not rare after acute PE in this Chinese population, especially within 3 years of diagnosis. Lower-limb varicose veins, intermediate-risk PE with elevated SPAP in the acute phase, and residual emboli during follow-up might increase the risk of CTEPH.

Entities:  

Keywords:  China; Incidence; chronic thromboembolic pulmonary hypertension (CTEPH); pulmonary embolism (PE); risk factors

Year:  2015        PMID: 26716031      PMCID: PMC4669266          DOI: 10.3978/j.issn.2072-1439.2015.11.43

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  28 in total

1.  Long-term outcomes in acute pulmonary thromboembolism: the incidence of chronic thromboembolic pulmonary hypertension and associated risk factors.

Authors:  Ahmet Korkmaz; Tevfik Ozlu; Savas Ozsu; Zeynep Kazaz; Yilmaz Bulbul
Journal:  Clin Appl Thromb Hemost       Date:  2012-01-23       Impact factor: 2.389

2.  Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study.

Authors:  Eric Hachulla; Virginie Gressin; Loïc Guillevin; Patrick Carpentier; Elisabeth Diot; Jean Sibilia; André Kahan; Jean Cabane; Camille Francès; David Launay; Luc Mouthon; Yannick Allanore; Kiet Phong Tiev; Pierre Clerson; Pascal de Groote; Marc Humbert
Journal:  Arthritis Rheum       Date:  2005-12

Review 3.  Diagnostic management of clinically suspected acute pulmonary embolism.

Authors:  M V Huisman; F A Klok
Journal:  J Thromb Haemost       Date:  2009-07       Impact factor: 5.824

Review 4.  Update on chronic thromboembolic pulmonary hypertension.

Authors:  Irene Marthe Lang; Michael Madani
Journal:  Circulation       Date:  2014-08-05       Impact factor: 29.690

Review 5.  Pulmonary embolism and deep vein thrombosis.

Authors:  Samuel Z Goldhaber; Henri Bounameaux
Journal:  Lancet       Date:  2012-04-10       Impact factor: 79.321

6.  Echocardiographic assessment of pulmonary arterial pressure in the follow-up of patients with pulmonary embolism.

Authors:  Remedios Otero; Mikel Oribe; Aitor Ballaz; David Jimenez; Fernando Uresandi; Dolores Nauffal; Francisco Conget; Consolación Rodriguez; Teresa Elias; Luis Jara; Aurelio Cayuela; Isabel Blanco; Joan Barberá
Journal:  Thromb Res       Date:  2011-01-17       Impact factor: 3.944

7.  Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism.

Authors:  Cecilia Becattini; Giancarlo Agnelli; Raffaele Pesavento; Mauro Silingardi; Renzo Poggio; Maria Rita Taliani; Walter Ageno
Journal:  Chest       Date:  2006-07       Impact factor: 9.410

Review 8.  Diagnosis and differential assessment of pulmonary arterial hypertension.

Authors:  Robyn J Barst; Michael McGoon; Adam Torbicki; Olivier Sitbon; Michael J Krowka; Horst Olschewski; Sean Gaine
Journal:  J Am Coll Cardiol       Date:  2004-06-16       Impact factor: 24.094

9.  Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC).

Authors:  Adam Torbicki; Arnaud Perrier; Stavros Konstantinides; Giancarlo Agnelli; Nazzareno Galiè; Piotr Pruszczyk; Frank Bengel; Adrian J B Brady; Daniel Ferreira; Uwe Janssens; Walter Klepetko; Eckhard Mayer; Martine Remy-Jardin; Jean-Pierre Bassand
Journal:  Eur Heart J       Date:  2008-08-30       Impact factor: 29.983

10.  Validation of a clinical prognostic model to identify low-risk patients with pulmonary embolism.

Authors:  D Aujesky; A Perrier; P-M Roy; R A Stone; J Cornuz; G Meyer; D S Obrosky; M J Fine
Journal:  J Intern Med       Date:  2007-06       Impact factor: 8.989

View more
  15 in total

1.  Diabetes mellitus is associated with increased bleeding in pulmonary embolism receiving conventional anticoagulant therapy: findings from a "real-world" study.

Authors:  Zhu Zhang; Zhenguo Zhai; Yuanhua Yang; Jun Wan; Wanmu Xie; Jianguo Zhu; Ying H Shen; Chen Wang
Journal:  J Thromb Thrombolysis       Date:  2017-05       Impact factor: 2.300

Review 2.  Models and Molecular Mechanisms of World Health Organization Group 2 to 4 Pulmonary Hypertension.

Authors:  Ping Yu Xiong; Francois Potus; Winnie Chan; Stephen L Archer
Journal:  Hypertension       Date:  2017-11-20       Impact factor: 10.190

3.  Multicentre observational screening survey for the detection of CTEPH following pulmonary embolism.

Authors:  Nicolas Coquoz; Daniel Weilenmann; Daiana Stolz; Vladimir Popov; Andrea Azzola; Jean-Marc Fellrath; Hans Stricker; Alberto Pagnamenta; Sebastian Ott; Silvia Ulrich; Sandor Györik; Jérôme Pasquier; John-David Aubert
Journal:  Eur Respir J       Date:  2018-04-04       Impact factor: 16.671

Review 4.  Application of pulmonary rehabilitation in patients with pulmonary embolism (Review).

Authors:  Aiping Yu; Weiping Ding; Wanmi Lin; Juan Cai; Weina Huang
Journal:  Exp Ther Med       Date:  2021-12-01       Impact factor: 2.447

Review 5.  Epidemiology and Pathophysiology of Chronic Thromboembolic Pulmonary Hypertension: Risk Factors and Mechanisms.

Authors:  Sarah Medrek; Zeenat Safdar
Journal:  Methodist Debakey Cardiovasc J       Date:  2016 Oct-Dec

6.  Vascular complications of sickle cell disease.

Authors:  Ashar Usmani; Roberto F Machado
Journal:  Clin Hemorheol Microcirc       Date:  2018       Impact factor: 2.375

7.  Evaluation of the Incidence of Chronic Thromboembolic Pulmonary Hypertension 1 Year After First Episode of Acute Pulmonary Embolism: A Cohort Study.

Authors:  Farid Rashidi; Rezayat Parvizi; Eisa Bilejani; Babak Mahmoodian; Fatemeh Rahimi; Ata Koohi
Journal:  Lung       Date:  2020-01-02       Impact factor: 2.584

8.  Incidence and risk factors of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a systematic review and meta-analysis of cohort studies.

Authors:  Meng Zhang; Ning Wang; Zhenguo Zhai; Mingyuan Zhang; Rongrong Zhou; Yanyan Liu; Yuanhua Yang
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

9.  Efficacy and safety of riociguat in the treatment of chronic thromboembolic pulmonary arterial hypertension: A meta-analysis.

Authors:  Miaofa Ying; Jin Song; Shenglong Gu; Rui Zhao; Mingxing Li
Journal:  Medicine (Baltimore)       Date:  2021-06-04       Impact factor: 1.817

Review 10.  Treatment of patients with chronic thrombo embolic pulmonary hypertension: focus on riociguat.

Authors:  Zachary R Smith; Charles T Makowski; Rana L Awdish
Journal:  Ther Clin Risk Manag       Date:  2016-06-10       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.